Optimizing the Management of HER2+ Inflammatory Breast Cancer

Video

Optimizing the Management of HER2+ Inflammatory Breast Cancer

60-year-old Woman WithHER2+ Inflammatory Breast Cancer

  • A 60-year-old woman presented to her gynecologist with redness, tenderness, and swelling of her right breast over the last 2 weeks
    • PMH: HTN managed with HCTZ/triamterene
    • FH: unremarkable
    • PE: palpable mass in the right inferior breast with skin thickening; no palpable lymphadenopathy
    • ROS: clear, no fever
  • Breast ultrasound revealed a solid right-sided 3.8-cm mass at the 10:00 position with no posterior acoustic shadowing; abnormal enlargement of 2 right axillary lymph nodes
  • Core needle biopsy of the breast mass revealed high grade infiltrating ductal carcinoma;HER2+
  • Fine needle biopsy of a right axillary node confirmed carcinoma
  • Punch biopsy of the skin showed dermal lymphatic invasion with carcinoma cells
  • PET/CT staging showed increased uptake over right breast, diffusely, and with at least 2 nodes seen in the right axillary basin; no evidence of distant metastases
  • Clinical staging: T4dN1M0
  • She received neoadjuvant therapy consisting of dose-dense AC X 4-THP X 4; physical exam was consistent with a complete clinical response
  • She then underwent right modified radical mastectomy; pathology showed a complete pathologic response
  • Following surgery, she was treated with adjuvant trastuzumab + pertuzumab to complete one year of monoclonal antibody therapy
  • The patient completed radiation therapy to the right chest wall and regional nodes
  • She was placed on letrozole
Related Videos
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content